Treatment burden of medicare beneficiaries with stage i non-small-cell lung cancer

Carolyn J. Presley, Pamela R. Soulos, Mary Tinetti, Victor M. Montori, James B. Yu, Cary P. Gross

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Purpose To quantify the burden and complexity associated with treatment of Medicare beneficiaries with stage I non-small-cell lung cancer (NSCLC). Methods Using the SEER-Medicare database, we conducted a retrospective cohort study of Medicare beneficiaries who were diagnosed with stage I NSCLC from 2007 to 2011 and who were treated with surgery, stereotactic body radiation therapy, or external beam radiation therapy. Main outcome measures were the number of days a patient was in contact with the health care system (encounter days), the number of physicians involved in a patient's care, and the number of medications prescribed. Logistic regression modeled the association between patient characteristics, treatment type, and high treatment burden (defined as $ 66 encounter days). Results Onaverage, 7,955 patients spent 1 in 3 days interacting with the health care system during the initial 60 days of treatment. Patients experienced a median of 44 encounter days with high variability (interquartile range [IQR], 29 to 66) in the 12 months after treatment initiation. The median number of physicians involved was 20 (IQR, 14 to 28), and the mediannumberof medications prescribedwas12(IQR,8to17). Patientswhowere treated with surgery had high treatment burden (predicted probability, 21.6%; 95% CI, 20.2 to 23.1) compared with patients who were treated with stereotactic body radiation therapy (predicted probability, 16.1%; 95% CI, 12.9 to 19.3), whereas patients who were treated with external beam radiation therapy had the highest burden (predicted probability, 46.8%; 95% CI, 43.3 to 50.2). Conclusion The treatment burden imposed on patients with early-stage NSCLC was substantial in terms of the number of encounters, physicians involved, and medications prescribed. Because treatment burden varied markedly across patients and treatment types, future work should identify opportunities to understand and ameliorate this burden.

Original languageEnglish (US)
Pages (from-to)e98-e107
JournalJournal of oncology practice
Issue number2
StatePublished - Feb 1 2017

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy


Dive into the research topics of 'Treatment burden of medicare beneficiaries with stage i non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this